mru buy move higher dose
aml rest pipelin track w/ updat guid
messag mru provid result larg line
investor expect highlight includ protocol amend on-going phase
 bispecif evalu higher dose level think
could potenti suggest lower-than-expect toxic amend
phase i/ii trial evalu monotherapi bispecif
solid tumor harbor fusion pipelin updat combin
studi egfr bispecif remain track guidanc
data readout maintain maintain buy rate pt
buy rate mru pt pleas see next-gen antibodi platform
initi note believ mru differenti bispecif antibodi technolog
platform allow rapid product candid screen lead optim main
valu driver stock lie earli pipelin consist
bispecif egfr view
potenti differenti target acut myeloid leukemia aml
limit express profil rel commonly-target receptor
combin mru lower-affin arm theoret reduc severity/
frequenc cytokin releas syndrom believ offer differenti
profil rel t-cell engag aml therapi current model po
remain cautiou given modest histor singl agent efficaci observ
date histor difficulti antibodies/bispecif competit
sever agent link believ valu current stock
preliminari anti tumor activ observ dose
escal result push previous base evalu higher
dose recal design lower-affin arm aml-
select target see next-gen antibodi initi potenti enhanc
safeti profil engag via reduc cytokin releas syndrom theoret
spare erythrocyt platelet progenitor cell mru amend phase dose
escal trial juli allow explor higher dose note
preliminari anti-tumor activ observ dose escal
initi readout schedul previous
phase ii combin data track readout
monotherapi cohort amend focu gene fusion recal
undergo combin studi cohort breast cancer
well monotherapi studi monotherapi amend gene fusion-
posit solid tumor re-focus genetically-defin biomark present
test solid cancer sampl link includ nsclc
link pancreat cancer link code ligand
tyrosin kinas fusion activ oncogen
akt signal pan-erbb inhibitor associ durabl respons
patient lung adenocarcinoma
rest pipelin track mru expect initi clinic data
egfr ye line prior guidanc emerg data phase trial
includ safeti inform around recommend phase dose expect
end accord mru management plan provid guidanc
program mru also note phase dose escal expans
trial asset partner progress
plan furthermor on-going collabor
page analyst certif import disclosur
yield bispecif antibodi current phase trial
autoimmun diseas mru elig addit clinic mileston
ono collabor well mid-singl digit royalti net sale
updat estim account result mru end quarter
cash cash equival invest modestli adjust oper expens
light result maintain buy pt
page analyst certif import disclosur
valuat risk
arriv price target mru use discount cash flow analysi
use wacc consist clinical-stag
biotech compani cover proof-of-concept data well termin
growth rate risk includ regulatori commerci setback potenti
emerg new competitor lower product sale expect
page analyst certif import disclosur
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
